Skip to main content

ORIGINAL RESEARCH article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1521629
This article is part of the Research Topic Harnessing Molecular Insights for Enhanced Drug Sensitivity and Immunotherapy in Cancer View all 6 articles

PAQR6 as a Prognostic Biomarker and Potential Therapeutic Target in Kidney Renal Clear Cell Carcinoma

Provisionally accepted
Tao Zou Tao Zou 1Zongming Jia Zongming Jia 1*Jixiang Wu Jixiang Wu 1*Xuxu Liu Xuxu Liu 2*Minghao Deng Minghao Deng 3*Xuefeng Zhang Xuefeng Zhang 1*Yuxin Lin Yuxin Lin 1,4*Jigen Ping Jigen Ping 1*
  • 1 Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Liaoning Province, China
  • 2 Department of Neurology, Children’s Hospital of Chongqing Medical University, Chongqing, China
  • 3 Nantong Hospital of Traditional Chinese Medicine, Nantong, Jiangsu Province, China
  • 4 Center for Systems Biology, Soochow University, Suzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

    Background: Progestin And AdipoQ Receptor Family Member VI (PAQR6) plays a significant role in the non-genomic effects of rapid steroid responses and is abnormally expressed in various tumors. However, its biological function in kidney renal clear cell carcinoma (KIRC) and its potential as a therapeutic target remain underexplored.Methods: In this study, PAQR6 was identified as a critical oncogene by WGCNA algorithm and differential gene expression analysis using TCGA -KIRC and GSE15641 data. The differences in PAQR6 expression and its association with KIRC survival outcomes were investigated, and transcriptomic data were used to further elucidate PAQR6's biological functions. Moreover, XCELL and single -cell analysis assessed the correlation between PAQR6 expression and immune infiltration.TIDE algorithm was used to assess how well various patient cohorts responded to immune checkpoint therapy. Finally, the role of PAQR6 in the development of KIRC was verified through EdU, scratch assays, and Transwell assays.Results: Our findings suggest that elevated expression of PAQR6 is linked to a bad prognosis for KIRC patients. Functional enrichment analysis demonstrated that PAQR6 is primarily involved in angiogenesis and pluripotent stem cell differentiation, which are crucial in mediating the development of KIRC. Additionally, we established a ceRNA network that is directly related to overall prognosis, further supporting the role of PAQR6 as a prognostic biomarker for KIRC.Using both computational and experimental methods, this study leads the charge in discovering and verifying PAQR6 as a prognostic biomarker and possible therapeutic target for KIRC.In the future, to determine its molecular mechanism in KIRC carcinogenesis, more in vivo research will be carried out.

    Keywords: kidney renal clear cell carcinoma, Immune infiltration, prognostic biomarker, PAQR6, Angiogenesis

    Received: 02 Nov 2024; Accepted: 03 Dec 2024.

    Copyright: © 2024 Zou, Jia, Wu, Liu, Deng, Zhang, Lin and Ping. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zongming Jia, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Liaoning Province, China
    Jixiang Wu, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Liaoning Province, China
    Xuxu Liu, Department of Neurology, Children’s Hospital of Chongqing Medical University, Chongqing, China
    Minghao Deng, Nantong Hospital of Traditional Chinese Medicine, Nantong, 226000, Jiangsu Province, China
    Xuefeng Zhang, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Liaoning Province, China
    Yuxin Lin, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Liaoning Province, China
    Jigen Ping, Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Liaoning Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.